Quick Answer
Aspira Women’s Health Inc. reported Total Revenue of $9.18 million for fiscal year 2024.
Aspira Women’s Health Inc. — Key Financials by Year
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Total Revenue | $9.18M +0.3% |
$9.15M +11.9% |
$8.18M +20.1% |
$6.81M +46.5% |
$4.65M +2.5% |
$4.54M +48.6% |
| Revenue (ASC 606) | $9.18M +0.3% |
$9.15M | — | — | — | — |
| Net Income | -$13.09M +21.5% |
-$16.69M +44.2% |
-$29.89M +5.6% |
-$31.66M -76.8% |
-$17.91M -17.5% |
-$15.24M -34.0% |
| Diluted EPS | -$0.93 +48.6% |
-$1.81 +53.0% |
-$3.85 -1275.0% |
-$0.28 | — | — |
| Total Assets | $5.49M -12.3% |
$6.26M -64.0% |
$17.37M -57.7% |
$41.08M +109.5% |
$19.61M +41.8% |
$13.83M +21.2% |
| Cash and Equivalents | $1.77M -31.9% |
$2.60M -80.5% |
$13.31M -64.2% |
$37.18M +123.6% |
$16.63M | — |
| Long-Term Debt | $1.28M -10.6% |
$1.43M -38.2% |
$2.31M -14.8% |
$2.72M -21.8% |
$3.48M +216.4% |
$1.10M -14.9% |
| Stockholders Equity | -$2.56M -8.4% |
-$2.37M -133.9% |
$6.98M -76.9% |
$30.17M +210.4% |
$9.72M +11.2% |
$8.74M +22.2% |
| R&D Expense | $3.27M -19.1% |
$4.04M -31.8% |
$5.92M +11.3% |
$5.31M +152.6% |
$2.10M +106.7% |
$1.02M +85.1% |
| Operating Income | -$16.28M +13.7% |
-$18.85M +39.5% |
-$31.14M +4.5% |
-$32.59M -81.3% |
-$17.98M -17.7% |
-$15.28M -34.8% |
| Gross Profit | $5.48M +4.1% |
$5.26M +21.7% |
$4.32M +41.2% |
$3.06M +147.7% |
$1.24M +3.4% |
$1.20M +1442.7% |
| Shares Outstanding | 17.41M +63.5% |
10.65M +28.2% |
8.31M -92.6% |
112.14M +7.2% |
104.62M +7.5% |
97.29M +28.9% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $2.31M | +2.1% | -4.1% |
| Revenue (ASC 606) | September 30, 2025 | $2.31M | +2.1% | -4.1% |
| Net Income | September 30, 2025 | -$4.89M | -37.9% | -83.5% |
| Diluted EPS | September 30, 2025 | -$0.13 | +43.5% | -85.7% |
| Total Assets | September 30, 2025 | $7.30M | +53.3% | +47.9% |
| Cash and Equivalents | September 30, 2025 | $3.81M | +78.6% | +146.5% |
| Long-Term Debt | September 30, 2025 | $1.10M | -17.5% | -5.2% |
| Stockholders Equity | September 30, 2025 | -$4.34M | -72.4% | -61.8% |
| R&D Expense | September 30, 2025 | $739.0K | -18.6% | +5.0% |
| Operating Income | September 30, 2025 | -$1.58M | +57.8% | +12.8% |
| Gross Profit | September 30, 2025 | $1.38M | +2.1% | -9.8% |
| Shares Outstanding | September 30, 2025 | 42.66M | +161.9% | +19.7% |
- Aspira Women’s Health Inc. reported Total Revenue of $9.18 million for fiscal year 2024.
- Aspira Women’s Health Inc. showed an increase of +0.3% in Total Revenue compared to the prior fiscal year.
- Aspira Women’s Health Inc. reported Revenue (ASC 606) of $9.18 million for fiscal year 2024.
- Aspira Women’s Health Inc. showed an increase of +0.3% in Revenue (ASC 606) compared to the prior fiscal year.
- Aspira Women’s Health Inc. reported Net Income of -$13.09 million for fiscal year 2024.
- Aspira Women’s Health Inc. showed an increase of +21.5% in Net Income compared to the prior fiscal year.
- Aspira Women’s Health Inc. reported Diluted EPS of $0.93 per share (loss) for fiscal year 2024.
- Aspira Women’s Health Inc. showed an increase of +48.6% in Diluted EPS compared to the prior fiscal year.
- Aspira Women’s Health Inc. reported Total Assets of $5.49 million for fiscal year 2024.
- Aspira Women’s Health Inc. showed a decrease of -12.3% in Total Assets compared to the prior fiscal year.
- Aspira Women’s Health Inc. reported Cash and Equivalents of $1.77 million for fiscal year 2024.
- Aspira Women’s Health Inc. showed a decrease of -31.9% in Cash and Equivalents compared to the prior fiscal year.
- Aspira Women’s Health Inc. reported Long-Term Debt of $1.28 million for fiscal year 2024.
- Aspira Women’s Health Inc. showed a decrease of -10.6% in Long-Term Debt compared to the prior fiscal year.
- Aspira Women’s Health Inc. reported Stockholders Equity of -$2.56 million for fiscal year 2024.
- Aspira Women’s Health Inc. showed a decrease of -8.4% in Stockholders Equity compared to the prior fiscal year.
- Aspira Women’s Health Inc. reported R&D Expense of $3.27 million for fiscal year 2024.
- Aspira Women’s Health Inc. showed a decrease of -19.1% in R&D Expense compared to the prior fiscal year.
- Aspira Women’s Health Inc. reported Operating Income of -$16.28 million for fiscal year 2024.
- Aspira Women’s Health Inc. showed an increase of +13.7% in Operating Income compared to the prior fiscal year.
- Aspira Women’s Health Inc. reported Gross Profit of $5.48 million for fiscal year 2024.
- Aspira Women’s Health Inc. showed an increase of +4.1% in Gross Profit compared to the prior fiscal year.
- Aspira Women’s Health Inc. reported Shares Outstanding of 17.41 million shares for fiscal year 2024.
- Aspira Women’s Health Inc. showed an increase of +63.5% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: